| Name | Title | Contact Details |
|---|
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.
South Florida Baptist Hospital, Inc is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. South Florida Baptist Hospital, Inc is based in Plant City, FL. You can find more information on South Florida Baptist Hospital, Inc at www.sjbhealth.org
Sunrise Dental Lab is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Buck Institute is committed to providing a strong benefits package as part of its total compensation program.
SilverCloud Health is the world`s leading digital mental health company, enabling healthcare organizations to deliver clinically validated digital therapeutic care that improves outcomes, increases access and scale while reducing costs.